Key facts
- CS Pharmaceuticals’s last known valuation is $39.1M (Dec 2025).
- It has raised $11.9M.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for CS Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for CS Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CS Pharmaceuticals
Developer of ophthalmology and rare disease pharmaceuticals designed to address unmet medical needs in specialty therapeutic areas. The company focuses on discovering, in-licensing, and developing drug candidates that target the underlying pathophysiology of meibomian gland dysfunction and associated dry eye disease, with activities spanning molecule selection, preclinical evaluation, clinical trial design, and regulatory preparation, enabling ophthalmology specialists and healthcare providers to access new treatment options that address unmet clinical needs in ocular surface care.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 7
- Website
- cspharmaceuticals.com/
- Ownership
- Privately Held (backing)
CS Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CS Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CS Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.